The clinical utility of ADAMTS13 activity, antigen and autoantibody assays in thrombotic thrombocytopenic purpura
- 3 January 2007
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 136 (4), 649-655
- https://doi.org/10.1111/j.1365-2141.2006.06471.x
Abstract
Thrombotic thrombocytopenic purpura (TTP) has been linked to a severe deficiency in ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 motif, member 13) activity. Since the identification of ADAMTS13, and its target cleavage sequence in von Willebrand factor (VWF), several novel ADAMTS13 activity, antigen and autoantibody assays have been developed. Our aim was to evaluate the potential use of these novel assays. ADAMTS13 activity and inhibitors were measured by overnight incubation of patient plasma with pure VWF followed by multimer or collagen binding analysis. ADAMTS13 activity (Rapid peptide assay), antigen and immunoglobulin G anti-ADAMTS13 were measured by enzyme-linked immunosorbent assay. 118 samples from seven TTP patients (six adult idiopathic, one congenital) were studied longitudinally during episodes of TTP, their treatment and prophylaxis. ADAMTS13 antigen levels varied considerably between patients and sample times, but in new cases of acute TTP, rapid assays of ADAMTS13 antigen, on serial samples, maybe helpful in confirming the diagnosis. The rapid peptide ADAMTS13 activity assay showed good concordance of results with the older activity assay methods. The change in ADAMTS13 activity mirrored the autoantibody level and in 5/6 acquired TTP cases, a fall in antibody appeared to predict a rise in ADAMTS13 activity, potentially allowing modification of patient management based on autoantibody levels.Keywords
This publication has 13 references indexed in Scilit:
- Successful management of pregnancy in women with a history of thrombotic thrombocytopaenic purpuraBlood Coagulation & Fibrinolysis, 2006
- Analysis on the Molecular Species and Concentration of Circulating ADAMTS13 in BloodThe Journal of Biochemistry, 2006
- Prognostic value of inhibitory anti‐ADAMTS13 antibodies in adult‐acquired thrombotic thrombocytopenic purpuraBritish Journal of Haematology, 2005
- Coagulation factor levels in cryosupernatant prepared from plasma treated with amotosalen hydrochloride (S‐59) and ultraviolet A lightTransfusion, 2005
- Proteolytic inactivation of ADAMTS13 by thrombin and plasminBlood, 2005
- VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13Blood, 2004
- An enzyme immunoassay of ADAMTS13 distinguishes patients with thrombotic thrombocytopenic purpura from normal individuals and carriers of ADAMTS13 mutationsThrombosis and Haemostasis, 2004
- von Willebrand factor-cleaving protease activity in congenital thrombotic thrombocytopenic purpuraBritish Journal of Haematology, 2000
- von Willebrand factor‐cleaving protease activity in congenital thrombotic thrombocytopenic purpuraBritish Journal of Haematology, 2000
- Unusually Large Plasma Factor VIII: von Willebrand Factor Multimers in Chronic Relapsing Thrombotic Thrombocytopenic PurpuraThe New England Journal of Medicine, 1982